Perrigo (PRGO) Stock Price, News & Analysis

Company Overview

Perrigo Company plc is a leading global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals. The company develops, manufactures and distributes a broad portfolio of branded and private-label products spanning pain relief, digestive health, vitamins, minerals and supplements, infant formulas, and women’s health. Perrigo’s offerings are sold through supermarket chains, pharmacies, mass merchandisers, and healthcare providers under both its own labels and those of retail partners.

Founded in 1887 in Allegan, Michigan, Perrigo has grown from a regional supplier to a global healthcare manufacturer by combining organic innovation with strategic acquisitions. In 1999, Perrigo re-domiciled to Ireland, establishing a presence in Europe and positioning itself to expand into new markets. Over the decades, Perrigo has integrated manufacturing facilities, R&D centers and distribution networks in the United States, Europe, the Middle East and Africa, allowing the company to serve more than 100 countries worldwide.

The company operates four key business segments: Consumer Self Care–North America, Consumer Self Care–International, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients (APIs). Its North America arm focuses on store-brand OTC and nutritional products, while the international segment supplies branded and private-label products across Europe, the Middle East and emerging markets. Perrigo’s prescription division concentrates on generic pharmaceuticals, delivering cost-effective alternatives to branded drugs, and its API unit manufactures key chemical components for both internal use and external customers.

Perrigo is led by President and Chief Executive Officer Eyal Desheh and supported by a seasoned executive team with experience in pharmaceuticals, consumer goods and global supply chain management. The board emphasizes quality, regulatory compliance and innovation, investing in new product development and digital capabilities to enhance customer engagement. With a commitment to affordability, accessibility and consumer well-being, Perrigo continues to expand its footprint in core markets while pursuing strategic growth opportunities across the healthcare landscape.

Key Stats

• Today's Range: $27.06 to $27.70
• 50-Day Range: $24.62 to $27.60
• 52-Week Range: $23.14 to $30.93
• Volume: 1.03 million shs
• Average Volume: 1.44 million shs
• Market Capitalization: $3.75 billion
• P/E Ratio: N/A
• Dividend Yield: 4.25%
• Price Target: $33.00
• Consensus Rating: Hold

Perrigo Stock Analysis - MarketRank™

Perrigo scored higher than 97% of companies evaluated by MarketBeat, and ranked 40th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Perrigo has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Perrigo has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 19.53%

Earnings Growth

Earnings for Perrigo are expected to grow by 19.53% in the coming year, from $2.56 to $3.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Perrigo is -20.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Perrigo is -20.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Perrigo has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.63% of the float of Perrigo has been sold short.

Short Interest Ratio / Days to Cover

Perrigo has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Perrigo has recently decreased by 5.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Perrigo is a leading dividend payer. It pays a dividend yield of 4.26%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Perrigo has been increasing its dividend for 23 years.

Dividend Sustainability

Based on earnings estimates, Perrigo will have a dividend payout ratio of 37.91% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.93

Percentage of Shares Shorted

3.63% of the float of Perrigo has been sold short.

Short Interest Ratio / Days to Cover

Perrigo has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Perrigo has recently decreased by 5.16%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.98

News Sentiment

Perrigo has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Perrigo this week, compared to 7 articles on an average week.

Search Interest

Only 3 people have searched for PRGO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Perrigo to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Perrigo insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.70% of the stock of Perrigo is held by insiders.

Percentage Held by Institutions

95.91% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRGO Stock Analysis - Frequently Asked Questions

How have PRGO shares performed this year?

Perrigo's stock was trading at $25.71 at the beginning of 2025. Since then, PRGO stock has increased by 6.1% and is now trading at $27.28.

How were Perrigo's earnings last quarter?

Perrigo Company plc (NYSE:PRGO) released its earnings results on Wednesday, May, 7th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.04. The company's revenue for the quarter was down 3.5% compared to the same quarter last year.
Read the conference call transcript.

Does Perrigo have any subsidiaries?

Perrigo subsidiaries include HRA Pharma, Ranir, Laboratoire de la Mer SAS, Geiss Destin & Dunn, ScarAway, Omega Pharma, Elan Corporation, and more.

Who are Perrigo's major shareholders?

Top institutional investors of Perrigo include Harbor Capital Advisors Inc. (0.04%), Wealth Enhancement Advisory Services LLC (0.01%), Parallel Advisors LLC and MassMutual Private Wealth & Trust FSB. Insiders that own company stock include Svend Andersen, Ronald Craig Janish, Geoffrey M Parker, James E Dillard III, Robert Willis, Patrick Lockwood-Taylor, Alison Ives, Grainne Quinn, Eduardo Guarita Bezerra, Katherine C Doyle, Jeffrey B Kindler, Thomas Farrington and Murray S Kessler.
View institutional ownership trends.

How do I buy shares of Perrigo?

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Perrigo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Perrigo investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/07/2025
• Record date for 6/17 Dividend: 5/30/2025
• Ex-Dividend for 6/17 Dividend: 5/30/2025
• Dividend Payable: 6/17/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PRGO
• CIK: 1585364
• Web: www.perrigo.com
• Phone: (531) 709-4000
• Fax: 269-673-9128
• Employees: 8,379
• Year Founded: 1887

Price Target and Rating

• Average Price Target for Perrigo: $33.00
• High Price Target: $42.00
• Low Price Target: $27.00
• Potential Upside/Downside: +21.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 10.66
• P/E Growth: N/A
• Net Income: -$171.80 million
• Net Margins: -4.16%
• Pretax Margin: 0.60%
• Return on Equity: 8.93%
• Return on Assets: 3.87%

Debt

• Debt-to-Equity Ratio: 0.82
• Current Ratio: 2.36
• Quick Ratio: 1.28

Sales & Book Value

• Annual Sales: $4.37 billion
• Price / Sales: 0.86
• Cash Flow: $5.06 per share
• Price / Cash Flow: 5.39
• Book Value: $31.66 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 137,480,000
• Free Float: 136,515,000
• Market Cap: $3.75 billion
• Optionable: Optionable
• Beta: 0.45